<DOC>
	<DOCNO>NCT01015612</DOCNO>
	<brief_summary>To evaluate performance , efficacy safety percutaneous implantation CoreValve® prosthetic aortic valve patient severe symptomatic native aortic valve stenosis elevate surgical risk</brief_summary>
	<brief_title>CoreValve® System Australia/New Zealand Clinical Study</brief_title>
	<detailed_description>Prospective , non-randomized , single-arm multi-center trial conduct common protocol 10 center Australia New Zealand .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Inclusion Criteria 1 . Documented severe aortic valve stenosis 2 . Access vessel diameter &gt; 6 mm define pre procedure via angiographic measure 3 . Aortic valve annulus diameter ≥ 20 mm &lt; 29 mm define pre procedure echocardiographic measure 4 . Ascending aorta diameter ≤ 43 mm sinotubular junction 5 . Native aortic valve disease , define valve stenosis aortic valve area &lt; 1cm2 ( &lt; 0.6cm2 /m2 ) define pre procedure echocardiographic measure AND ( Assessment Surgical Risk ) Age ≥ 80 year AND/OR Surgical risk calculate logistic EuroSCORE ≥ 20 % , AND/OR Age ≥ 65 year one two ( 2 ) follow criterion : Cirrhosis liver ( Child class A B ) Pulmonary insufficiency : VMS &lt; 1 liter Previous cardiac surgery ( CABG , valvular surgery ) Porcelain aorta Pulmonary hypertension &gt; 60 mmHg high probability cardiac surgery valve replacement Recurrent pulmonary embolus Right ventricular insufficiency Thoracic burning sequela contraindicate open chest surgery History mediastinum radiotherapy Severe connective tissue disease result contraindication surgery Cachexia ( clinical impression ) 6 . Study subject must willing able attend followup visit within specified visit window , agree undergo protocol evaluation visit 1 . Known hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , nitinol , porcine product , contrast medium adequately premedicated 2 . Any sepsis , include active endocarditis . 3 . Recent myocardial infarction ( &lt; 30 day ) 4 . Any leave ventricular atrial thrombus determine pre procedure echocardiography 5 . Uncontrolled atrial fibrillation 6 . Mitral tricuspid valvular insufficiency ( &gt; grade II ) 7 . Previous aortic valve replacement ( mechanical valve stented bioprosthetic valve ) 8 . Evolutive recent CVA ( cerebrovascular accident ) , ( &lt; 3 month ) 9 . Femoral , iliac aortic vascular condition ( e.g . stenosis , tortuosity ) , make impossible insertion endovascular access aortic valve 10 . Symptomatic carotid vertebral artery narrow ( &gt; 70 % ) disease 11 . Abdominal thoracic aortic aneurysm 12 . Bleeding diathesis coagulopathy , patient refuse blood transfusion 13 . Evolutive disease life expectancy le one year 14 . Creatinine clearance &lt; 20 ml/min 15 . Active gastritis know peptic ulcer disease 16 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Aortic Valve Stenosis</keyword>
	<keyword>Aortic Valve Insufficiency</keyword>
</DOC>